Corey, Victoria C.Lukens, AmandaIstvan, Eva S.Lee, Marcus C. S.Franco, VirginiaMagistrado, PamelaCoburn-Flynn, OliviaSakata-Kato, TomoyoFuchs, OliviaGnädig, Nina F.Goldgof, GregLinares, MariaGomez-Lorenzo, Maria G.De Cózar, CristinaLafuente-Monasterio, Maria JosePrats, SaraMeister, StephanTanaseichuk, OlgaWree, MelanieZhou, YingyaoWillis, Paul A.Gamo, Francisco-JavierGoldberg, Daniel E.Fidock, David A.Wirth, DyannWinzeler, Elizabeth A.2016-07-142016Corey, V. C., A. K. Lukens, E. S. Istvan, M. C. S. Lee, V. Franco, P. Magistrado, O. Coburn-Flynn, et al. 2016. “A broad analysis of resistance development in the malaria parasite.” Nature Communications 7 (1): 11901. doi:10.1038/ncomms11901. http://dx.doi.org/10.1038/ncomms11901.2041-1723http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662239Microbial resistance to chemotherapy has caused countless deaths where malaria is endemic. Chemotherapy may fail either due to pre-existing resistance or evolution of drug-resistant parasites. Here we use a diverse set of antimalarial compounds to investigate the acquisition of drug resistance and the degree of cross-resistance against common resistance alleles. We assess cross-resistance using a set of 15 parasite lines carrying resistance-conferring alleles in pfatp4, cytochrome bc1, pfcarl, pfdhod, pfcrt, pfmdr, pfdhfr, cytoplasmic prolyl t-RNA synthetase or hsp90. Subsequently, we assess whether resistant parasites can be obtained after several rounds of drug selection. Twenty-three of the 48 in vitro selections result in resistant parasites, with time to resistance onset ranging from 15 to 300 days. Our data indicate that pre-existing resistance may not be a major hurdle for novel-target antimalarial candidates, and focusing our attention on fast-killing compounds may result in a slower onset of clinical resistance.en-USJournal Article2016-07-1410.1038/ncomms11901